Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed Release™ (PTR™) drug delivery platform, today announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs. The open-access manuscript provides clinicians and researchers with pharmacokinetic data supporting CTx-1301 (dexmethylphenidate HCl), Cingulate's lead product candidate for the treatment of attention-deficit/hyperactivity disorder (ADHD).

Available through open access, the manuscript expands Cingulate's growing body of peer-reviewed evidence supporting CTx-1301 and follows the recent publication of the Company's Phase 3 efficacy and safety study in the Journal of Child and Adolescent Psychopharmacology.